IP Library Granted Patent US 11,357,813
Granted Patent B2
US 11,357,813 · App. 15/753,608 · Granted Jun 14, 2022

Composition comprising tannins

Inventors: Emiliano Giovagnoni (Sansepolcro, IT); Michele Burini (Sansepolcro, IT); Francesca Marini (Sansepolcro, IT)
Assignee: ABOCA S.P.A. SOCIETÀ AGRICOLA
A61K36/49A23L33/105A61K9/0014A61K36/185A61K36/28A61K36/324A61K36/328A61K36/45A61K36/73A61K36/886A61P1/04A61P17/02A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,357,813
App. No.
15/753,608
Granted
Jun 14, 2022
Kind
B2
Abstract

The present invention relates to a novel composition capable of enhancing tannins' ability to adhere to mucous membranes (mucosas) and skin, its use as a therapeutic composition, and products consisting of or comprising said composition.

Claims (28)

1. A composition comprising by weight percent thereof:

from 0.05 to 1% w/w of resins,

from 0.05 to 1% w/w of tannins, and

from 0.05 to 3% w/w of polysaccharides,

wherein the composition is in the form suitable for treating a mucosal or skin tissue, and wherein the amounts of said resins, tannins, and polysaccharides are therapeutically effective amounts sufficient to provide increased mucosal or skin adhesion versus a reference tannin composition lacking said amounts of resins and/or polysaccharides.

2. The composition according to claim 1 , comprising

from 0.1 to 0.7% w/w of resins,

from 0.1 to 0.8% w/w of tannins, and

from 0.1 to 1.5% w/w of polysaccharides.

3. The composition according to claim 1 , comprising

from 0.1 to 0.5% w/w of resins,

from 0.2 to 0.7% w/w of tannins, and

from 0.1 to 0.8% w/w of polysaccharides.

4. The composition according to claim 1 , wherein said resins and/or wherein said tannins and/or wherein said polysaccharides are of natural origin.

5. The composition according to claim 1 , wherein said tannins are hydrolisable tannins and/or condensed tannins.

6. The composition according to claim 1 , wherein said resins are extracted from and/or are comprised in extracts of Commiphora myrrha and/or of Boswellia spp.

7. The composition according to claim 1 , wherein said tannins are extracted from and/or are comprised in extracts of one or more selected from the group consisting of Agrimonia eupatoria, Hamamelis Virginiana, Vaccinium myrtillus, Quercus robur, Potentilla anserina , and Rosa centifolia.

8. The composition according to claim 1 , wherein said polysaccharides are extracted from and/or are comprised in extracts of one or more selected from the group consisting of Aloe vera, Matricaria chamomilla , and Althaea officinalis.

9. The composition according to claim 1 , further comprising at least one edible and/or pharmaceutically acceptable carrier and/or diluent and/or excipient.

10. The composition according to claim 1 , which is for topical use in the form of cream, pomade, ointment, spray, gel, suppository, or ovule; or for oral use in the form of a capsule, a tablet, a pill, a hard gelatine, a soft gelatine, a granule, a powder, a syrup, an elixir, a suspension, an emulsion, a spray, or in the form of aerosol.

11. The composition according to claim 1 , which is a pharmaceutical composition, is comprised in or consists in a food supplement, is comprised in or consists in a medical device, is comprised in or consists in a medical food, or is comprised in or consists in a nutraceutical.

12. A nutraceutical medical device, food supplement, or medical food comprising a composition according to claim 1 .

13. A method of using a composition according to claim 1 for medical treatment, wherein said method comprises administering a therapeutically effective amount of said composition to a subject in need thereof.

14. The method according to claim 13 , for treatment of mucosal inflammation, skin inflammation, mucosal or skin ulcer, mucosal or skin wound, or burning.

15. The method according to claim 14 , for treatment of enteritis, Crohn's disease, ulcerous colitis, gastritis, esophagitis, mucosal or skin ulcer, pharynx inflammation, sore throat, cough, burning, eczema, viral infection, or a disease of buccal, pharynx, gastric, airway, intestinal, uterine, or rectal mucosa.

16. The method according to claim 13 , wherein said composition further comprises at least one edible and/or pharmaceutically acceptable carrier and/or diluent and/or excipient.

17. The method according to claim 13 , wherein said composition is for topical use in the form of cream, pomade, ointment, spray, gel, suppository, ovule; or for oral use in the form of a capsule, a tablet, a pill, a hard gelatine, a soft gelatine, a granule, a powder, a syrup, an elixir, a suspension, an emulsion, a spray, or in the form of aerosol.

18. The method according to claim 13 , wherein said composition is a pharmaceutical composition, is comprised in or consists in a food supplement, is comprised in or consists in a medical device, is comprised in or consists in a medical food, or comprised in or consists in a nutraceutical.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2019
From: GIOVAGNONI, EMILIANO; BURINI, MICHELE; MARINI, FRANCESCA
To: ABOCA S.P.A. SOCIETA AGRICOLA
Reel/Frame 048785/0562 →
Priority Claims (1)
IT 102015000045541 · Aug 20, 2015 · national
Continuity (1)
Related Publication 20190125817A1 · May 2, 2019